Effect of anticoagulant/antiplatelet therapy on the development and progression of diabetic retinopathy

  • Chi-Juei Jeng (Creator)
  • Yi Ting Hsieh (Creator)
  • Cheng Li Lin (Creator)
  • I. Jong Wang (Creator)



Abstract Background We investigated whether antiplatelet/anticoagulant (APAC) therapy can protect patients with type 2 diabetes mellitus (T2DM) from the development or progression of diabetic retinopathy (DR). Methods This is a retrospective cohort study using Longitudinal Health Insurance Database in Taiwan. A total of 73,964 type 2 diabetic patients older than 20 years old were included. Hazard ration (HR) of non-proliferative DR (NPDR), proliferative DR (PDR), and diabetic macular edema (DME) were analyzed with APAC usage as a time-dependent covariate. Age, sex, comorbidities, and medicines were further adjusted in a multi-variable model. Contributions of respective APAC was investigated with sensitivity analysis. Results Compared with nonusers, APAC users had a lower cumulative incidence of NPDR (P
Date made available2022

Cite this